Total
0
Shares
Alcidion Group (ASX:ALC) - Managing Director, Kate Quirke - The Market Herald
Managing Director, Kate Quirke
Source: Finfeed
  • Alcidion Group (ALC) has signed a 12-month, $560,000 contract with Sydney Local Health District (LHD) for its Miya Precision platform
  • Miya Precision combines AI-based predictive analysis, clinical support, and mobile alerts in an easy-to-use dashboard
  • This contract will see Miya Precision be deployed to Sydney LHD's virtual hospital which is being used for COVID-19 positive patients who are in home isolation
  • Patients will have their statuses displayed in real-time, as well as other relevant information to allow for the best possible care
  • Alcidion is up 10.3 per cent on the market and shares are currently trading for 16 cents each

Alcidion Group (ALC) has signed a 12-month, $560,000 contract with Sydney Local Health District (LHD) for its Miya Precision platform.

Miya Precision combines AI-based predictive analysis, clinical support, and mobile alerts in an easy-to-use dashboard.

This contract will see the Miya Precision platform be deployed to Sydney LHD's virtual hospital, rpavirtual, which is being used for COVID-19 positive patients who are in home isolation.

"Miya Precision has the potential to provide valuable support for some critical short-term requirements for Sydney LHD, but also provides us with a platform to continue to innovate the delivery of patient care across the entire district," Sydney LHD Chief Information Officer Richard Taggart said.

Patients will have their statuses displayed in real-time, as well as other relevant information to allow for the best possible care.

This reduces the risk of infection for healthcare workers, and the need for personal protective equipment (PPE).

"We are delighted to enter into this partnership with Sydney LHD. We have moved quickly to enable an initial rollout that addresses the short-term challenges raised by COVID-19," Alcidion Managing Director Kate Quirke commented.

"The engagement allows us to demonstrate the value of our platform in one of the busiest hospitals in Australia operating across metropolitan Sydney, in the same way as we have done with the deployment at Murrumbidgee LHD for the rural sector," she added.

Alcidion is up 10.3 per cent on the market and shares are trading for 16 cents each at 1:39 pm AEST.


Subscribe


ALC by the numbers
More From The Market Herald
LBT Innovations (ASX:LBT) - CEO & Managing Director, Brent Barnes - The Market Herald

" LBT Innovations (ASX:LBT) partners with oneservice for APAS Independence

Biotech company LBT Innovations (LBT) has signed a partnership with oneservice for its APAS Independence product.
Avita Medical (ASX:AVH) - CEO, Dr Michael Perry - The Market Herald

" Avita Therapeutics (ASX:AVH) signs US$7.6M agreement with BARDA

Regenerative medicine company Avita Therapeutics (AVH) has teamed up with Biomedical Advanced Research and Development Authority (BARDA) for its RECELL System.
Race Oncology (ASX:RAC) - COO, Dr Daniel Tillett - The Market Herald

" Race Oncology (ASX:RAC) secures $3M from biotech investors

Race Oncology (RAC) has secured a $3 million strategic investment from three biotechnology investors.
Imagion Biosystems (ASX:IBX) - CEO & Executive Chairman, Bob Proulx - The Market Herald

" Imagion Biosystems (ASX:IBX) gains access to Boston University’s imaging tech

Cancer detection company Imagion Biosystems (IBX) will work with Boston University on the next generation of imaging technology.